{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:17:15Z","timestamp":1761895035647},"reference-count":15,"publisher":"American Diabetes Association","issue":"5","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":4216,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,5,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To investigate relationships between baseline factors and treatment-associated efficacy changes in type 2 diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Multivariable analyses of treatment response in 1,229 type 2 diabetic patients with hypercholesterolemia who received ezetimibe\/simvastatin or atorvastatin in a randomized double-blind 6-week study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Increasing age was related to improvements in all lipid assessments. Men had greater triglyceride and non-HDL cholesterol reductions than women, and black\/Hispanic patients had less favorable lipid effects than other races\/ethnicities. Increasing baseline LDL cholesterol was associated with improvements in most lipids; higher baseline non-HDL cholesterol with improved HDL cholesterol and triglycerides; higher baseline HDL cholesterol with greater non-HDL cholesterol and high-sensitivity C-reactive protein (hs-CRP) reductions; and higher baseline hs-CRP with smaller LDL cholesterol, non-HDL cholesterol, and apolipoprotein B reductions. Patients with high baseline non-HDL cholesterol or triglycerides less frequently attained LDL cholesterol targets. Obesity was inversely related to HDL cholesterol and hs-CRP changes, and higher baseline A1C to smaller apolipoprotein B reductions. Metabolic syndrome was not a significant predictor.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Treatment responses in type 2 diabetic patients were related to baseline factors, although treatment effects (ezetimibe\/simvastatin being more effective than atorvastatin) remained consistent. The presence of predictive factors should be considered in planning lipid-altering therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc09-1762","type":"journal-article","created":{"date-parts":[[2010,2,12]],"date-time":"2010-02-12T02:24:02Z","timestamp":1265941442000},"page":"1021-1024","update-policy":"http:\/\/dx.doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":15,"title":["Relationships Between Metabolic Syndrome and Other Baseline Factors and the Efficacy of Ezetimibe\/Simvastatin and Atorvastatin in Patients With Type 2 Diabetes and Hypercholesterolemia"],"prefix":"10.2337","volume":"33","author":[{"given":"Ronald B.","family":"Goldberg","sequence":"first","affiliation":[{"name":"University of Miami Miller School of Medicine, Miami, Florida;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Guyton","sequence":"additional","affiliation":[{"name":"Duke University, Durham, North Carolina;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore","family":"Mazzone","sequence":"additional","affiliation":[{"name":"University of Illinois, Chicago, Illinois;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth S.","family":"Weinstock","sequence":"additional","affiliation":[{"name":"State University of New York Upstate Medical University and VA Medical Center, Syracuse, New York;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam B.","family":"Polis","sequence":"additional","affiliation":[{"name":"Merck, North Wales, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Tipping","sequence":"additional","affiliation":[{"name":"Merck, North Wales, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne E.","family":"Tomassini","sequence":"additional","affiliation":[{"name":"Merck, North Wales, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Tershakovec","sequence":"additional","affiliation":[{"name":"Merck, North Wales, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2010,2,11]]},"reference":[{"key":"2022031218190968400_B1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"2022031218190968400_B2","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"2022031218190968400_B3","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2337\/dc08-9018","article-title":"Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation","volume":"31","author":"Brunzell","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031218190968400_B4","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.amjcard.2005.09.134","article-title":"Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmaeogenetics (CAP) Study","volume":"97","author":"Simon","year":"2006","journal-title":"Am J Cardiol"},{"key":"2022031218190968400_B5","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0002-9149(02)02599-7","article-title":"Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS)","volume":"90","author":"Streja","year":"2002","journal-title":"Am J Cardiol"},{"key":"2022031218190968400_B6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/01.mol.0000137225.46654.4d","article-title":"Phenotypes, genotypes and response to statin therapy","volume":"15","author":"Caslake","year":"2004","journal-title":"Curr Opin Lipidol"},{"key":"2022031218190968400_B7","first-page":"1579","article-title":"Ezetimibe\/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study","author":"Goldberg","year":"2006"},{"key":"2022031218190968400_B8","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1161\/01.CIR.85.4.1293","article-title":"Expanded Clinical Evaluation of Lovastatin (Excel) study results: effect of patient characteristics on lovastatin-induced changes in plasma-concentrations of lipids and lipoproteins","volume":"85","author":"Shear","year":"1992","journal-title":"Circulation"},{"key":"2022031218190968400_B9","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.2337\/diacare.28.10.2472","article-title":"Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the Diabetes Prevention Program","volume":"28","author":"Diabetes Prevention Program Research Group.","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031218190968400_B10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1365-2796.1997.00238.x","article-title":"The influence of age on low density lipoprotein metabolism: effects of cholestyramine treatment in young and old healthy male subjects","volume":"242","author":"Ericsson","year":"1997","journal-title":"J Intern Med"},{"key":"2022031218190968400_B11","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.107.708388","article-title":"Variation in the 3- hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment","volume":"117","author":"Krauss","year":"2008","journal-title":"Circulation"},{"key":"2022031218190968400_B12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1194\/jlr.M600167-JLR200","article-title":"Age-related impairment of HDL-mediated cholesterol efflux","volume":"48","author":"Berrougui","year":"2007","journal-title":"J Lipid Res"},{"key":"2022031218190968400_B13","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(06)69292-1","article-title":"Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study","volume":"368","author":"Deedwania","year":"2006","journal-title":"Lancet"},{"key":"2022031218190968400_B14","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1038\/oby.2007.342","article-title":"Effect of obesity on high-density lipoprotein metabolism","volume":"15","author":"Rashid","year":"2007","journal-title":"Obesity"},{"key":"2022031218190968400_B15","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0009-9120(03)00109-7","article-title":"Low-density lipoprotein subclass and its correlating factors in diabetics","volume":"36","author":"Lee","year":"2003","journal-title":"Clin Biochem"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/33\/5\/1021\/605728\/zdc00510001021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/33\/5\/1021\/605728\/zdc00510001021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T19:20:12Z","timestamp":1647112812000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/33\/5\/1021\/27044\/Relationships-Between-Metabolic-Syndrome-and-Other"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,11]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2010,2,11]]},"published-print":{"date-parts":[[2010,5,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc09-1762","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,11]]}}}